首页> 美国卫生研究院文献>Journal of Neural Transplantation >Endophilin2 Interacts with GluA1 to Mediate AMPA Receptor Endocytosis Induced by Oligomeric Amyloid-β
【2h】

Endophilin2 Interacts with GluA1 to Mediate AMPA Receptor Endocytosis Induced by Oligomeric Amyloid-β

机译:Endophilin2与GluA1相互作用介导寡聚淀粉样β诱导的AMPA受体内吞作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Amyloid-β (Aβ) plays an important role in Alzheimer's disease (AD), as oligomeric Aβ induces loss of postsynaptic AMPA receptors (AMPARs) leading to cognitive deficits. The loss of postsynaptic AMPARs is mediated through the clathrin-dependent endocytosis pathway, in which endophilin2 is one of the important regulatory proteins. Endophilin2, which is enriched in both the pre- and postsynaptic membrane, has previously been reported to be important for recycling of synaptic vesicles at the presynaptic membrane. However, the role of endophilin2 in oligomeric Aβ-induced postsynaptic AMPAR endocytosis is not well understood. In this study, we show that endophilin2 does not affect constitutive AMPAR endocytosis. Endophilin2 knockdown, but not overexpression, resisted oligomeric Aβ-induced AMPAR dysfunction. Moreover, endophilin2 colocalized and interacted with GluA1, a subunit of AMPAR, to regulate oligomeric Aβ-induced AMPAR endocytosis. Thus, we have determined a role of endophilin2 in oligomeric Aβ-induced postsynaptic AMPAR dysfunction, indicating possible directions for preventing the loss of AMPARs in cognitive impairment and providing evidence for the clinical treatment of AD.
机译:淀粉样蛋白-β(Aβ)在阿尔茨海默氏病(AD)中起重要作用,因为寡聚Aβ导致突触后AMPA受体(AMPAR)丢失,从而导致认知缺陷。突触后AMPAR的丢失是通过网格蛋白依赖性内吞途径介导的,其中endophilin2是重要的调节蛋白之一。以前已经报道了在突触前和突触后膜中都富集的Endophilin2对于在突触前膜的突触小泡的再循环很重要。然而,关于endophilin2在寡聚Aβ诱导的突触后AMPAR内吞作用中的作用尚不清楚。在这项研究中,我们表明endophilin2不会影响AMPAR的内吞作用。 Endophilin2敲低,但不是过表达,抵抗寡聚Aβ诱导的AMPAR功能障碍。此外,endophilin2与AMPAR的亚基GluA1共定位并相互作用,以调节寡聚Aβ诱导的AMPAR内吞作用。因此,我们已经确定了endophilin2在寡聚Aβ诱导的突触后AMPAR功能障碍中的作用,为预防AMPAR在认知障碍中的丧失提供了可能的方向,并为AD的临床治疗提供了证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号